Results from a phase Ib/II study (TBCRC032) investigating the safety and efficacy of enzalutamide alone, or in combination with the PI3K inhibitor taselisib in patients with metastatic AR+ (≥10%) breast cancer, showed that the combination of enzalutamide and taselisib increased CBR in TNBC patients with AR+ tumours [53]. This evidence concerns the gene PIK3CG and neoplasm.